{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:57:13Z","timestamp":1781679433054,"version":"3.54.5"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009076","name":"University of Science and Technology of China","doi-asserted-by":"publisher","award":["ZD-YG-202413"],"award-info":[{"award-number":["ZD-YG-202413"]}],"id":[{"id":"10.13039\/501100009076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2020-MS-225"],"award-info":[{"award-number":["2020-MS-225"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Hebei Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["H2023209001"],"award-info":[{"award-number":["H2023209001"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA013330"],"award-info":[{"award-number":["P30CA013330"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cellsig.2025.112108","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:13:31Z","timestamp":1756826011000},"page":"112108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting YES1 enhances the efficacy of chemotherapy, targeted therapy and onco-immunotherapy"],"prefix":"10.1016","volume":"136","author":[{"given":"Dayong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"5293","key":"10.1016\/j.cellsig.2025.112108_bb0010","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.cellsig.2025.112108_bb0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.cellsig.2025.112108_bb0020","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon","year":"2021","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.cellsig.2025.112108_bb0025","first-page":"239","article-title":"Protein tyrosine kinases, with emphasis on the Src family","volume":"5","author":"Courtneidge","year":"1994","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13058-022-01596-y","article-title":"SRC kinase-mediated signaling pathways and targeted therapies in breast cancer","volume":"24","author":"Luo","year":"2022","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.cellsig.2025.112108_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115333","article-title":"The potent role of Src kinase-regulating glucose metabolism in cancer","volume":"206","author":"Shao","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0040","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1006\/geno.1993.1086","article-title":"Chromosomal reassignment: YACs containing both YES1 and thymidylate synthase map to the short arm of chromosome 18","volume":"15","author":"Silverman","year":"1993","journal-title":"Genomics"},{"issue":"22","key":"10.1016\/j.cellsig.2025.112108_bb0045","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1158\/0008-5472.CAN-18-3376","article-title":"YES1 is a targetable oncogene in cancers harboring YES1 gene amplification","volume":"79","author":"Hamanaka","year":"2019","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.cellsig.2025.112108_bb0050","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-13-1854","article-title":"Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-yes\/YAP axis","volume":"20","author":"Touil","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12964-021-00750-x","article-title":"Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition","volume":"19","author":"Ortiz","year":"2021","journal-title":"Cell Commun. Signal"},{"issue":"9","key":"10.1016\/j.cellsig.2025.112108_bb0060","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.febslet.2007.03.059","article-title":"Crystallographic structure of the SH3 domain of the human c-yes tyrosine kinase: loop flexibility and amyloid aggregation","volume":"581","author":"Mart\u00edn-Garc\u00eda","year":"2007","journal-title":"FEBS Lett."},{"issue":"Pt 7","key":"10.1016\/j.cellsig.2025.112108_bb0065","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1242\/jcs.034843","article-title":"Differential trafficking of Src, Lyn, Yes and Fyn is specified by the state of palmitoylation in the SH4 domain","volume":"122","author":"Sato","year":"2009","journal-title":"J. Cell Sci."},{"issue":"10","key":"10.1016\/j.cellsig.2025.112108_bb0070","first-page":"2563","article-title":"Cellular interactions of CRKL, and SH2-SH3 adaptor protein","volume":"54","author":"ten Hoeve","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2025.112108_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1479-5876-10-97","article-title":"The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer","volume":"10","author":"Natsume","year":"2012","journal-title":"J. Transl. Med."},{"issue":"47","key":"10.1016\/j.cellsig.2025.112108_bb0080","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1038\/onc.2012.590","article-title":"Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth","volume":"32","author":"Yeung","year":"2013","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0085","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.celrep.2016.05.094","article-title":"MEIS2 is an oncogenic partner in AML1-ETO-positive AML","volume":"16","author":"Vegi","year":"2016","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112108_bb0090","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s41388-021-02163-z","article-title":"Correction to: EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis","volume":"41","author":"Mao","year":"2022","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.cellsig.2025.112108_bb0095","first-page":"606","article-title":"ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1\/YAP axis","volume":"21","author":"Tan","year":"2024","journal-title":"Cancer Biol. Med."},{"issue":"11","key":"10.1016\/j.cellsig.2025.112108_bb0100","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-16-2300","article-title":"SFK\/FAK signaling attenuates Osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer","volume":"77","author":"Ichihara","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2025.112108_bb0105","article-title":"SRC family kinase inhibition targets YES1 and YAP1 as primary drivers of lung cancer and as mediators of acquired resistance to ALK and epidermal growth factor receptor inhibitors","volume":"6","author":"Sato","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41419-022-04500-w","article-title":"Linc01133 contributes to gastric cancer growth by enhancing YES1-dependent YAP1 nuclear translocation via sponging miR-145-5p","volume":"13","author":"Sun","year":"2022","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.cellsig.2025.112108_bb0115","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-18-2297","article-title":"Targeting purinergic receptor P2Y2 prevents the growth of pancreatic ductal adenocarcinoma by inhibiting cancer cell glycolysis","volume":"25","author":"Hu","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.cellsig.2025.112108_bb0120","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1158\/0008-5472.CAN-19-3853","article-title":"Targeting hippo-dependent and hippo-independent YAP1 signaling for the treatment of childhood rhabdomyosarcoma","volume":"80","author":"Slemmons","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188341","article-title":"Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy","volume":"1873","author":"Reggiani","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0130","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/s41467-020-15301-0","article-title":"YAP1\/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity","volume":"11","author":"Yuan","year":"2020","journal-title":"Nat. Commun."},{"issue":"Pt 7","key":"10.1016\/j.cellsig.2025.112108_bb0135","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1242\/jcs.075796","article-title":"Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF","volume":"124","author":"Tamm","year":"2011","journal-title":"J. Cell Sci."},{"issue":"48","key":"10.1016\/j.cellsig.2025.112108_bb0140","doi-asserted-by":"crossref","first-page":"33492","DOI":"10.1074\/jbc.M114.580076","article-title":"Serum inter-\u03b1-inhibitor activates the Yes tyrosine kinase and YAP\/TEAD transcriptional complex in mouse embryonic stem cells","volume":"289","author":"Pijuan-Galit\u00f3","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cellsig.2025.112108_bb0145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","article-title":"The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells","volume":"147","author":"Cordenonsi","year":"2011","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.cellsig.2025.112108_bb0150","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2021.02.019","article-title":"Scribble sub-cellular localization modulates recruitment of YES1 to regulate YAP1 phosphorylation","volume":"28","author":"Zhao","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.cellsig.2025.112108_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.656359","article-title":"SCRIB promotes proliferation and metastasis by targeting hippo\/YAP Signalling in colorectal cancer","volume":"9","author":"Shen","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.cellsig.2025.112108_bb0160","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.cell.2012.11.026","article-title":"\u0392-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis","volume":"151","author":"Rosenbluh","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.cellsig.2025.112108_bb0165","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/0008-5472.CAN-20-2801","article-title":"YAP and \u03b2-catenin cooperate to drive oncogenesis in basal breast cancer","volume":"81","author":"Quinn","year":"2021","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.cellsig.2025.112108_bb0170","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1158\/0008-5472.CAN-19-2995","article-title":"Personalized cancer therapy: YES1 is the new kid on the block","volume":"79","author":"Rai","year":"2019","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.cellsig.2025.112108_bb0175","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1158\/1535-7163.MCT-21-0964","article-title":"Opposite effects of Src family kinases on YAP and ERK activation in pancreatic cancer cells: implications for targeted therapy","volume":"21","author":"Sinnett-Smith","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"10.1016\/j.cellsig.2025.112108_bb0180","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1038\/s41388-021-01786-6","article-title":"EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis","volume":"40","author":"Mao","year":"2021","journal-title":"Oncogene"},{"issue":"31","key":"10.1016\/j.cellsig.2025.112108_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400115","article-title":"A novel tsRNA, m(7)G-3\u2019 tiRNA Lys(TTT), promotes bladder cancer malignancy via regulating ANXA2 phosphorylation","volume":"11","author":"Ying","year":"2024","journal-title":"Adv. Sci."},{"issue":"10","key":"10.1016\/j.cellsig.2025.112108_bb0190","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/1947601910395583","article-title":"Identification of the YES1 kinase as a therapeutic target in basal-like breast cancers","volume":"1","author":"Bilal","year":"2010","journal-title":"Genes Cancer"},{"issue":"10","key":"10.1016\/j.cellsig.2025.112108_bb0195","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s41416-024-02875-5","article-title":"The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy","volume":"131","author":"Egeland","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0200","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1756-9966-29-116","article-title":"Elevated c-Src and c-yes expression in malignant skin cancers","volume":"29","author":"Lee","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.cellsig.2025.112108_bb0205","doi-asserted-by":"crossref","first-page":"18526","DOI":"10.1074\/jbc.M110.164798","article-title":"Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3","volume":"286","author":"Hamamura","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.cellsig.2025.112108_bb0210","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1164\/rccm.201807-1292OC","article-title":"YES1 drives lung cancer growth and progression and predicts sensitivity to Dasatinib","volume":"200","author":"Garmendia","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.cellsig.2025.112108_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001496","article-title":"SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation","volume":"9","author":"Redin","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.cellsig.2025.112108_bb0220","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jtho.2022.08.002","article-title":"YES1 is a Druggable oncogenic target in SCLC","volume":"17","author":"Redin","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cellsig.2025.112108_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: an update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.cellsig.2025.112108_bb0230","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejmech.2019.03.025","article-title":"Anti-tubulin agents of natural origin: targeting taxol, vinca, and colchicine binding domains","volume":"171","author":"Naaz","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cellsig.2025.112108_bb0235","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cellsig.2018.09.007","article-title":"Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy","volume":"52","author":"Wang","year":"2018","journal-title":"Cell. Signal."},{"issue":"9","key":"10.1016\/j.cellsig.2025.112108_bb0240","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4161\/cc.10.9.15495","article-title":"Clues for c-yes involvement in the cell cycle and cytokinesis","volume":"10","author":"Jung","year":"2011","journal-title":"Cell Cycle"},{"issue":"21","key":"10.1016\/j.cellsig.2025.112108_bb0245","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1158\/0008-5472.CAN-23-2558","article-title":"Targeting YES1 disrupts mitotic Fidelity and potentiates the response to Taxanes in triple-negative breast cancer","volume":"84","author":"Piemonte","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0250","first-page":"133","article-title":"FOLFOX and FOLFIRI use in stage IV Colon Cancer: analysis of SEER-Medicare data","volume":"18","author":"Neugut","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12935-021-02412-x","article-title":"miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy","volume":"22","author":"Zhou","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.cellsig.2025.112108_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102436","article-title":"Beyond HER2: targeting the ErbB receptor family in breast cancer","volume":"109","author":"Drago","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171356","article-title":"Yes1 signaling mediates the resistance to Trastuzumab\/lap atinib in breast cancer","volume":"12","author":"Takeda","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cellsig.2025.112108_bb0270","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.cellsig.2025.112108_bb0275","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.cellsig.2025.112108_bb0280","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.cellsig.2025.112108_bb0285","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s41416-020-0952-1","article-title":"YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer","volume":"123","author":"Wang","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"23","key":"10.1016\/j.cellsig.2025.112108_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312809","article-title":"YES1 as a therapeutic target for HER2-positive breast cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) resistance development","volume":"22","author":"Fujihara","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188549","article-title":"HER2-targeted therapies in gastric cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"8","key":"10.1016\/j.cellsig.2025.112108_bb0300","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1111\/cas.14089","article-title":"Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells","volume":"110","author":"Yoshioka","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cellsig.2025.112108_bb0305","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"13","key":"10.1016\/j.cellsig.2025.112108_bb0310","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.cellsig.2025.112108_bb0315","doi-asserted-by":"crossref","first-page":"e6030","DOI":"10.1073\/pnas.1717782115","article-title":"YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics","volume":"115","author":"Fan","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.cellsig.2025.112108_bb0320","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00204-024-03693-7","article-title":"YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer","volume":"98","author":"Kook","year":"2024","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1470-2045(10)70289-8","article-title":"Cetuximab in NSCLC: another trial needed","volume":"12","author":"Perrone","year":"2011","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.cellsig.2025.112108_bb0330","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/onc.2012.90","article-title":"Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor","volume":"32","author":"Iida","year":"2013","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.cellsig.2025.112108_bb0335","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/1541-7786.MCR-24-0309","article-title":"Exploiting YES1-driven EGFR expression improves the efficacy of EGFR inhibitors","volume":"23","author":"Cuellar-Vite","year":"2025","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"10.1016\/j.cellsig.2025.112108_bb0340","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0345","article-title":"YES1 and MYC amplifications as synergistic resistance mechanisms to different generation ALK tyrosine kinase inhibitors in advanced NSCLC: brief report of clinical and preclinical proofs","volume":"3","author":"Minari","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"5","key":"10.1016\/j.cellsig.2025.112108_bb0350","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","article-title":"Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"6411","key":"10.1016\/j.cellsig.2025.112108_bb0355","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0360","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s13059-024-03435-z","article-title":"Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment","volume":"25","author":"Soupir","year":"2024","journal-title":"Genome Biol."},{"issue":"10","key":"10.1016\/j.cellsig.2025.112108_bb0365","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation","volume":"25","author":"Kreutzman","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0370","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519877321","article-title":"Effects of dasatinib on CD8(+)T, Th1, and Treg cells in patients with chronic myeloid leukemia","volume":"48","author":"Wei","year":"2020","journal-title":"J. Int. Med. Res."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0375","doi-asserted-by":"crossref","first-page":"eaav2437","DOI":"10.1126\/sciadv.aav2437","article-title":"Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy","volume":"5","author":"Tu","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cellsig.2025.112108_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0385","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1083\/jcb.200408130","article-title":"Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis","volume":"167","author":"Weis","year":"2004","journal-title":"J. Cell Biol."},{"issue":"24","key":"10.1016\/j.cellsig.2025.112108_bb0390","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1161\/CIRCULATIONAHA.122.061900","article-title":"Targeting VEGF-A\/VEGFR2 Y949 signaling-mediated vascular permeability alleviates hypoxic pulmonary hypertension","volume":"146","author":"Zhou","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112108_bb0395","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12943-024-02170-0","article-title":"Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells","volume":"23","author":"Xiao","year":"2024","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.cellsig.2025.112108_bb0400","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.bmcl.2013.05.072","article-title":"Identification of potent Yes1 kinase inhibitors using a library screening approach","volume":"23","author":"Patel","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.cellsig.2025.112108_bb0405","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.cellsig.2025.112108_bb0410","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1158\/0008-5472.CAN-21-0613","article-title":"A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability","volume":"81","author":"Temps","year":"2021","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.cellsig.2025.112108_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108876","article-title":"Paradoxical activation of c-Src as a drug-resistant mechanism","volume":"34","author":"Higuchi","year":"2021","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0420","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/13543784.2011.550873","article-title":"The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients","volume":"20","author":"Kruser","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"10","key":"10.1016\/j.cellsig.2025.112108_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27103060","article-title":"Bioactive Phytoconstituents as potent inhibitors of tyrosine-protein kinase YES (YES1): implications in anticancer therapeutics","volume":"27","author":"Yang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.cellsig.2025.112108_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116124","article-title":"Therapeutic strategy using novel RET\/YES1 dual-target inhibitor in lung cancer","volume":"171","author":"Choi","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112108_bb0435","first-page":"189","article-title":"Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma","volume":"2","author":"Wu","year":"2021","journal-title":"Nat. Can."},{"issue":"7","key":"10.1016\/j.cellsig.2025.112108_bb0440","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1535-7163.MCT-15-0554","article-title":"Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with Dasatinib","volume":"15","author":"Miller","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.cellsig.2025.112108_bb0445","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.201905-1092ED","article-title":"Predictive biomarkers of response to Src inhibitors in lung Cancer. Getting to YES1","volume":"200","author":"Li","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.cellsig.2025.112108_bb0450","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2217\/fon-2019-0690","article-title":"Linkage disequilibrium and haplotype analysis of Src and Yes1 genes in thyroid cancer","volume":"16","author":"Nisar","year":"2020","journal-title":"Future Oncol."},{"issue":"Pt 1","key":"10.1016\/j.cellsig.2025.112108_bb0455","article-title":"Ultrasensitive immunosensor for multiplex detection of cancer biomarkers carcinoembryonic antigen (CEA) and Yamaguchi sarcoma viral oncogene homolog 1 (YES1) based on eco-friendly synthesized gold nanoparticles","volume":"266","author":"Kiio","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.cellsig.2025.112108_bb0460","doi-asserted-by":"crossref","first-page":"10880","DOI":"10.1038\/ncomms10880","article-title":"A phosphotyrosine switch regulates organic cation transporters","volume":"7","author":"Sprowl","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2025.112108_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.644342","article-title":"Influence of YES1 kinase and tyrosine phosphorylation on the activity of OCT1","volume":"12","author":"Uddin","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825005236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825005236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:37:41Z","timestamp":1781678261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656825005236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":93,"alternative-id":["S0898656825005236"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.112108","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting YES1 enhances the efficacy of chemotherapy, targeted therapy and onco-immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.112108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112108"}}